Analysis of a Biotechnology Company — Intellect Neurosciences, Inc.
**Biological knowledge required**
Company name: Intellect Neurosciences, Inc.
Website: http://www.intellectns.com
The suggested content, assessment criteria, format, and referencing style will be uploaded in another word file.
Intellect Neurosciences, Inc., a bio pharmaceutical company, discovers and develops therapeutic agents for the treatment and prevention of neuro degenerative conditions primarily proteinopathies.
Under the agreements, the company has the first right to enforce the underlying intellectual property against unauthorized third parties.
The company’s therapeutic approach to proteinopathies aims to use antibodies or antibody drug conjugates to prevent the accumulation and neurotoxicity of aberrantly folded proteins that cause damage through oxidative stress and neuro inflammation.
The company’s focus on tau protein arises from increased understanding obtained during the past decade regarding the role of a certain abnormal form of this protein, known as Tau C3.
Tau is the major component of the neuro fibrillary tangles of Alzheimer disease.
In 2012, the company licensed a TauC3 antibody from Northwest University, acquiring worldwide rights to develop and commercialize the antibody.
The company is considering the use of antibody drug conjugates, in which two different molecules – an antibody and a small molecule – are combined chemically into a single entity.
The company purchased the original monoclonal antibody generated in mice from Immuno- Biological Laboratories in Japan and collaborated with London-based Medical Research Council Technology to create a humanized form, IN-N01.
The company has a license agreement with Northwestern University pursuant to which it obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sub licenses, under certain patents and know-how relating to the use of monoclonal antibody Tau C3 and TOC-1 for the prophylaxis, mitigation, diagnosis and/or treatment of AD and other tauopathies.
The company has a license agreement with AHP Manufacturing BV, acting through its Wyeth Medical Ireland Branch and Elan Pharma International Limited to provide Wyeth and Elan with certain license rights under certain of its patents and patent applications relating to certain antibodies that may serve as potential therapeutic products for the treatment for Alzheimer’s Disease.
Business Strategy The company’s core business strategy is to build a portfolio of compounds with the potential to treat or prevent neuro degenerative diseases, develop each compound to pre-determined milestones, and license the compounds to pharmaceutical companies for advanced development and commercialization.
Trademark The company owns ANTISENILIN trademark.
Research and Development For the June 30, 2015, the company’s research and development costs included $78,854. History Intellect Neurosciences, Inc. was founded in 2005.
